Page last updated: 2024-10-24

buspirone and Sclerosis, Systemic

buspirone has been researched along with Sclerosis, Systemic in 1 studies

Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Karamanolis, GP	1
Panopoulos, S	1
Denaxas, K	1
Karlaftis, A	1
Zorbala, A	1
Kamberoglou, D	1
Ladas, SD	1
Sfikakis, PP	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)[NCT02363478]			Early Phase 1	22 participants (Actual)	Interventional	2014-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes From Baseline in Manometric Parameters: Duration of Contractions at the Distal Part of the Esophagus at Week 4

(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Intervention	sec (Mean)
Buspirone	0.5

Changes From Baseline in Manometric Parameters: Velocity of Contractions at the Distal Part of the Esophagus at Week 4

(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Intervention	cm/sec (Mean)
Buspirone	0.3

Changes From Baseline in Manometric Parameters: i) Amplitude of Contractions at the Distal Part of the Esophagus and ii) Resting and Residual (Lower Esophageal Pressure) LES Pressure and IRP (Integrated Relaxation Pressure) at Week 4

(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Intervention	mmHg (Mean)
	amplitude	LES resting pressure	LES residual pressure	IRP
Buspirone	0.9	4.5	0.3	0.4

Changes in the Severity of Esophageal Symptoms at Week 4

Severity of esophageal symptoms (dysphagia, heartburn, regurgitation and chest pain) was measured on a 100-point visual analogue scale (VAS) ranging from 0 (absent) to 100 (very severe). Even minor decrease in the VAS score for each symptom at week 4 considered as improvement. (NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Intervention	units on a scale (Mean)
	heartburn	regurgitation	dysphagia	chest pain
Buspirone	14.9	13.2	6.9	1.9

Trials

1 trial available for buspirone and Sclerosis, Systemic

Article	Year
The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis research & therapy, 2016, 09-01, Volume: 18 Topics: Adult; Aged; Buspirone; Esophageal Motility Disorders; Esophagus; Female; Humans; Male; Manometry; M	2016